Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema
Conditions
Interventions
Factor XIIa antagonist monoclonal antibody
Placebo
Locations
16
United States
Donald S. Levy
Orange, California, United States
Allergy & Asthma Clinical Research
Walnut Creek, California, United States
Immunoe Health Centers
Centennial, Colorado, United States
Institute for Asthma and Allergy
Chevy Chase, Maryland, United States
The Mount Sinai Hospital
New York, New York, United States
Pennsylvania State University
Hershey, Pennsylvania, United States
Start Date
October 29, 2018
Primary Completion Date
October 15, 2021
Completion Date
October 15, 2021
Last Updated
November 8, 2022
NCT07298447
NCT06960213
NCT06842823
NCT06573723
NCT06634420
NCT05392114
Lead Sponsor
CSL Behring
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions